CYTH | Cyclo Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6000 - 0.6320
52 Week Range	0.5700 - 2.1200
Beta	0.82
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	26,548
Average Volume	32,601
Shares Outstanding	28,768,100
Market Cap	18,123,903
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2000-05-03

Valuation
Profitability
Growth
Health
P/E Ratio	-0.70
Forward P/E Ratio	N/A
EPS	-0.90
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

CYTH's peers: ATNX, MMNFF, LFCR, LSDI, GHSI, AGRX, TKNO, PTPI, PAHC, SHMN, SSIC, EGRX, ITCI, IRWD, AMRX, AQST, ASRT, ACRX, RDHL, SNPX, TXMD, ALVO

*Chart delayed

Analyzing fundamentals for CYTH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CYTH Fundamentals page.

Watching at CYTH technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CYTH Technicals page.